|1.||Jacques, Loretta: 13 articles (12/2015 - 01/2012)|
|2.||Woodcock, Ashley: 11 articles (12/2015 - 01/2012)|
|3.||Crim, Courtney: 11 articles (06/2015 - 07/2012)|
|4.||Bateman, Eric D: 10 articles (12/2015 - 01/2012)|
|5.||Church, Alison: 10 articles (09/2015 - 01/2014)|
|6.||Mehta, Rashmi: 8 articles (01/2015 - 12/2012)|
|7.||Bleecker, Eugene R: 8 articles (09/2014 - 01/2012)|
|8.||Lötvall, Jan: 8 articles (09/2014 - 01/2012)|
|9.||Busse, William W: 8 articles (09/2014 - 01/2012)|
|10.||O'Byrne, Paul M: 7 articles (12/2015 - 06/2013)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
12/15/2015 - "Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD."
01/01/2015 - "Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study."
01/01/2015 - "This review focuses on published clinical trials about the fixed-dose combination of umeclidinium/vilanterol trifenatate in patients with COPD. "
01/01/2015 - "Umeclidinium/vilanterol was not associated with a clinically relevant increased risk of cardiovascular adverse events in patients with COPD, when data from several clinical trials were pooled. "
12/01/2014 - "Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials."
|2.||Asthma (Bronchial Asthma)
09/01/2012 - "This study evaluated the novel, once-daily LABA vilanterol trifenatate (VI) in asthma patients who remained symptomatic despite existing ICS therapy. "
08/01/2012 - "Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial."
10/01/2013 - "FF is in development as a once-daily treatment for asthma as monotherapy and in combination with vilanterol (VI), a long-acting β2 agonist. "
07/01/2014 - "The long-acting muscarinic antagonist umeclidinium (UMEC) is approved as a monotherapy, and in combination with the long-acting β2-agonist vilanterol (VI), as a once-daily inhaled maintenance bronchodilator therapy for chronic obstructive pulmonary disease in the US and EU; they are not indicated for the treatment of asthma. "
04/01/2013 - "Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD."
06/01/2015 - "Improvement in trough forced expiratory volume in 1 s (FEV1) and the increased risk of pneumonia with fluticasone furoate and vilanterol compared with vilanterol alone were not associated with eosinophil count. "
01/01/2014 - "Cluster analysis using a data-driven recursive partitioning algorithm was employed using baseline data from two pooled one-year randomized exacerbation trials (n=3,255) of fluticasone furoate/vilanterol or vilanterol alone to identify distinct patient groups at greatest risk of pneumonia or serious (hospitalization or death) pneumonia. "
01/01/2014 - " increased non-fatal serious adverse pneumonia events (requiring hospital admission) (odds ratio (OR) 1.78, 95% confidence interval (CI) 1.50 to 2.12; 18 more per 1000 treated over 18 months; high quality), and no evidence suggested that this outcome was reduced by delivering it in combination with salmeterol or vilanterol (subgroup differences: I(2) = 0%, P value 0.51), or that different doses, trial duration or baseline severity significantly affected the estimate. "
09/01/2014 - "However, as with the long-term use of all ICS agents, 12-month data indicate an increase in the risk of pneumonia with fluticasone furoate/vilanterol. "
05/01/2013 - "Eight deaths from pneumonia were noted in the fluticasone furoate/vilanterol groups compared with none in the vilanterol only group. "
|4.||Dyspnea (Shortness of Breath)
01/01/2015 - "Results from six studies (five of them of 12 weeks' duration and one that lasted 1 year, including more than 6,000 patients in total) showed that umeclidinium/vilanterol trifenatate improved lung function, dyspnea, and health-related quality of life and decreased the exacerbation rate with no serious adverse events. "
|5.||Obstructive Lung Diseases (Obstructive Lung Disease)
|3.||Bronchodilator Agents (Bronchodilators)
|6.||Complement System Proteins (Complement)
|7.||fluticasone propionate - salmeterol combination
|8.||5- (2- (5,6- diethylindan- 2- ylamino)- 1- hydroxyethyl)- 8- hydroxy- 1H- quinolin- 2- one
|10.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|1.||Dry Powder Inhalers
|2.||Nebulizers and Vaporizers (Inhaler)